여성 피임약 시장 : 피임약, 피임기구, 유통 채널별 - 세계 예측(2025-2030년)

The Female Contraceptive Market was valued at USD 9.32 billion in 2023, expected to reach USD 9.91 billion in 2024, and is projected to grow at a CAGR of 6.41%, to USD 14.40 billion by 2030.

The female contraceptive market encompasses a broad range of products and technologies aimed at enabling women to prevent unwanted pregnancies and manage reproductive health efficiently. The necessity for these contraceptives stems from the ongoing demand for family planning, improved sexual health, and personal autonomy over reproductive choices. Applications are diverse, spanning from hormonal contraceptives like pills, patches, and injections to barrier methods such as female condoms and diaphragms, as well as long-acting reversible contraceptives (LARCs) including intrauterine devices (IUDs) and subdermal implants. End-use scope primarily involves individual consumers, healthcare providers, and family planning clinics. Market insights suggest that significant growth factors include increased awareness about sexual health, rising female employment driving the desire for controlled family planning, and governmental policies supporting contraceptive use. Technological advancements, such as the development of biodegradable and easy-to-administer methods, offer tremendous potential for market expansion. Nonetheless, challenges persist in the form of socio-cultural resistance in certain regions, limited access to healthcare services in low-income countries, and potential side effects associated with hormonal contraceptives that deter usage. Opportunities lie in investing in R&D for non-hormonal contraceptives that minimize side effects and innovations in digital health solutions that provide personalized contraceptive advice. Moreover, tapping into emerging markets with educational initiatives could pay dividends. Limitations include regulatory hurdles and predominantly conservative attitudes in parts of the world curtailing widespread adoption. For innovation, areas such as the development of male contraceptives to broaden the target audience and advances in biotechnology for safer, more effective solutions are promising. The market's nature is dynamic, with evolving consumer preferences and regulatory landscapes, necessitating adaptive strategies for sustained growth and market penetration. Engaging with cross-sector collaborations and leveraging new technological platforms for product development could bolster industry progress and address unmet needs in women's reproductive health.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Female Contraceptive Market

The Female Contraceptive Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Growing incidence of unwanted pregnancies and sexually transmitted diseases
  • Rising government initiatives to promote awareness regarding unintended pregnancies and increasing population
  • Multiple types and ease of availability of contraceptives
• Market Restraints
  • Side effects of contraceptive drugs
• Market Opportunities
  • Availability of contraceptives method such as Sino-Implants and novel contraceptive
  • Government and non-government organizations supporting programs to encourage contraception in emerging economies
• Market Challenges
  • Social stigma and misconceptions about different contraceptives

Porter's Five Forces: A Strategic Tool for Navigating the Female Contraceptive Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Female Contraceptive Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Female Contraceptive Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Female Contraceptive Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Female Contraceptive Market

A detailed market share analysis in the Female Contraceptive Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Female Contraceptive Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Female Contraceptive Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Female Contraceptive Market

A strategic analysis of the Female Contraceptive Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Female Contraceptive Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Afaxys Pharma, LLC, Agile Therapeutics, Amgen Inc., Ansell Ltd., Bayer AG, Cipla Limited, Cupid Limited, HLL Lifecare Limited, Johnson & Johnson Services, Inc., Mankind Pharma Ltd., Merck & Co., Inc., Mithra Pharmaceuticals S.A., Pfizer Inc., and The Cooper Companies, Inc..

Market Segmentation & Coverage

This research report categorizes the Female Contraceptive Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Contraceptive Drug, market is studied across Contraceptive Injections, Contraceptive Pills, Spermicides, and Topical Contraceptives. The Contraceptive Pills is further studied across Hormonal Pills and Non-Hormonal Pills.
• Based on Contraceptive Devices, market is studied across Contraceptive Patches, Contraceptive Sponges, Diaphragms & Caps, Female Condoms, Intra Uterine Contraceptive Devices, Sub-Dermal Contraceptive Implants, and Vaginal Rings.
• Based on Distribution Channel, market is studied across Clinic, Hospital Pharmacy, Independent Pharmacy, and Online Platform.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing incidence of unwanted pregnancies and sexually transmitted diseases
    • 5.1.1.2. Rising government initiatives to promote awareness regarding unintended pregnancies and increasing population
    • 5.1.1.3. Multiple types and ease of availability of contraceptives
  • 5.1.2. Restraints
    • 5.1.2.1. Side effects of contraceptive drugs
  • 5.1.3. Opportunities
    • 5.1.3.1. Availability of contraceptives method such as Sino-Implants and novel contraceptive
    • 5.1.3.2. Government and non-government organizations supporting programs to encourage contraception in emerging economies
  • 5.1.4. Challenges
    • 5.1.4.1. Social stigma and misconceptions about different contraceptives
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Female Contraceptive Market, by Contraceptive Drug

• 6.1. Introduction
• 6.2. Contraceptive Injections
• 6.3. Contraceptive Pills
  • 6.3.1. Hormonal Pills
  • 6.3.2. Non-Hormonal Pills
• 6.4. Spermicides
• 6.5. Topical Contraceptives

7. Female Contraceptive Market, by Contraceptive Devices

• 7.1. Introduction
• 7.2. Contraceptive Patches
• 7.3. Contraceptive Sponges
• 7.4. Diaphragms & Caps
• 7.5. Female Condoms
• 7.6. Intra Uterine Contraceptive Devices
• 7.7. Sub-Dermal Contraceptive Implants
• 7.8. Vaginal Rings

8. Female Contraceptive Market, by Distribution Channel

• 8.1. Introduction
• 8.2. Clinic
• 8.3. Hospital Pharmacy
• 8.4. Independent Pharmacy
• 8.5. Online Platform

9. Americas Female Contraceptive Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Female Contraceptive Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Female Contraceptive Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie Inc.
• 2. Afaxys Pharma, LLC
• 3. Agile Therapeutics
• 4. Amgen Inc.
• 5. Ansell Ltd.
• 6. Bayer AG
• 7. Cipla Limited
• 8. Cupid Limited
• 9. HLL Lifecare Limited
• 10. Johnson & Johnson Services, Inc.
• 11. Mankind Pharma Ltd.
• 12. Merck & Co., Inc.
• 13. Mithra Pharmaceuticals S.A.
• 14. Pfizer Inc.
• 15. The Cooper Companies, Inc.